US-based company MedRhythms has announced that its neurorehabilitation system InTandem is now available by prescription for adults living with chronic stroke walking impairments.
InTandem (MR-001) is designed to help walking and ambulation in adults with chronic stroke. The system delivers an intervention based on the principle of rhythmic auditory stimulation (RAS), a clinical intervention that utilises the mechanism through which the motor and auditory systems in the brain subconsciously synchronise to an external cue, such as music.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Over 3.5 million stroke survivors suffer from persistent walking deficits in the US, with the number estimated to rise by 465,000 individuals every year.
The US Food and Drug Administration (FDA) listed InTandem as a Class II medical device in July 2023, after receiving Breakthrough Device Designation in 2020.
InTandem is the only approved device in MedRhythms , however they have several ongoing clinical trials including MR-005 for Parkinson’s disease (NCT05421624), assessing whether amplifying physical activity through music programme is more effective than a standard-of-care walking programme in improving physical activity subjects with mild to moderate Parkinson’s.
Other products in MedRhythms pipeline include devices utilising RAS for the treatment of multiple sclerosis, brain diseases and cognitive disorders.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
